MXPA04004308A - Derivados de piridina como ligandos del receptor n-metil-d-aspartato (nmda). - Google Patents

Derivados de piridina como ligandos del receptor n-metil-d-aspartato (nmda).

Info

Publication number
MXPA04004308A
MXPA04004308A MXPA04004308A MXPA04004308A MXPA04004308A MX PA04004308 A MXPA04004308 A MX PA04004308A MX PA04004308 A MXPA04004308 A MX PA04004308A MX PA04004308 A MXPA04004308 A MX PA04004308A MX PA04004308 A MXPA04004308 A MX PA04004308A
Authority
MX
Mexico
Prior art keywords
hydrogen
lower alkyl
nmda receptor
receptor ligands
pyridine derivatives
Prior art date
Application number
MXPA04004308A
Other languages
English (en)
Inventor
Wyler Rene
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MXPA04004308A publication Critical patent/MXPA04004308A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invencion se refiere a compuestos de la formula (IA) o (B) donde R1 y R2 son independientemente entre si hidrogeno, alquilo inferior, -(CH2)n-OH, -(CH2)n-N(R6)2, -NR6C(O)C(O)O-alquilo inferior, -NR6-(CH2)n-OH, -NR6C(O)-alquilo inferior, -NH-bencilo o -NR6-(CH2)n-OH; R6 es independientemente entre si hidrogeno o alquilo inferior; R` es hidrogeno o alquilo inferior; R3 es hidrogeno o amino; R4 es hidrogeno o alquilo inferior; R5 es hidrogeno o halogeno; o R1 y R` pueden ser junto con los atomos de carbono a los cuales estan adheridos, el grupo -(CH2)4-; o R2 y R3 pueden ser junto con los atomos de carbono a los cuales estan adheridos, el grupo -N(R6)-CH2-; n es 0, 1, 2 o 3; y a sales de adicion acidas farmaceuticamente aceptables de los mismos. Ha sido demostrado que estos compuestos cuentan con un afinidad buena a receptores NMDA y pueden ser usados por si mismos para el tratamiento de enfermedades, relacionadas a este receptor.
MXPA04004308A 2001-11-09 2002-11-02 Derivados de piridina como ligandos del receptor n-metil-d-aspartato (nmda). MXPA04004308A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01126467 2001-11-09
PCT/EP2002/012240 WO2003040128A1 (en) 2001-11-09 2002-11-02 Pyridine derivatives as nmda receptor ligands

Publications (1)

Publication Number Publication Date
MXPA04004308A true MXPA04004308A (es) 2004-08-11

Family

ID=8179179

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04004308A MXPA04004308A (es) 2001-11-09 2002-11-02 Derivados de piridina como ligandos del receptor n-metil-d-aspartato (nmda).

Country Status (16)

Country Link
US (1) US6831087B2 (es)
EP (1) EP1448547B1 (es)
JP (1) JP4188837B2 (es)
KR (1) KR100589995B1 (es)
CN (1) CN100516061C (es)
AR (1) AR037221A1 (es)
AT (1) ATE293619T1 (es)
AU (1) AU2002351816B8 (es)
BR (1) BR0213977A (es)
CA (1) CA2467973C (es)
DE (1) DE60203820T2 (es)
ES (1) ES2240829T3 (es)
MX (1) MXPA04004308A (es)
PL (1) PL369544A1 (es)
RU (1) RU2303037C2 (es)
WO (1) WO2003040128A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007008816A (ja) * 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
MX2010003849A (es) 2007-10-18 2010-04-27 Boehringer Ingelheim Int Antagonistas de cgrp.
EP2065381A1 (de) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP Antagonisten
CA2705599A1 (en) * 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh New compounds
EP2062889A1 (de) * 2007-11-22 2009-05-27 Boehringer Ingelheim Pharma GmbH & Co. KG Verbindungen
EP2225223B1 (de) 2007-11-22 2017-01-11 Boehringer Ingelheim International GmbH Organische verbindungen
EA014100B1 (ru) * 2008-02-21 2010-08-30 Общество С Ограниченной Ответственностью "Валексфарм" Производные 2,4-диаминопиридина, фармацевтическая композиция, лекарственное средство на их основе для лечения или предупреждения заболеваний и нарушений, вызванных гиперактивацией nmda-рецепторов и/или в качестве стимуляторов когнитивных функций и способ лечения
RU2438672C1 (ru) * 2010-04-30 2012-01-10 Общество с ограниченной ответственностью "Клевер Фарм" Агент, проявляющий свойства активатора когнитивных функций (варианты)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
EP1080074B1 (de) * 1998-05-25 2006-11-08 Abbott GmbH & Co. KG Heterocyclische substituierte Amide, deren Herstellung und Verwendung
US6440995B1 (en) * 1999-10-01 2002-08-27 Hoffman-La Roche Inc. Quinolin-4-yl derivatives
DK1088818T3 (da) 1999-10-01 2005-03-14 Hoffmann La Roche Quinolin-4-yl-derivater
US6339093B1 (en) * 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives

Also Published As

Publication number Publication date
AR037221A1 (es) 2004-10-27
DE60203820D1 (de) 2005-05-25
KR100589995B1 (ko) 2006-06-19
BR0213977A (pt) 2004-08-31
AU2002351816B8 (en) 2008-04-03
CA2467973C (en) 2009-09-01
CA2467973A1 (en) 2003-05-15
WO2003040128A1 (en) 2003-05-15
EP1448547A1 (en) 2004-08-25
RU2004117595A (ru) 2006-01-10
DE60203820T2 (de) 2006-02-23
US6831087B2 (en) 2004-12-14
RU2303037C2 (ru) 2007-07-20
US20030119870A1 (en) 2003-06-26
KR20050042252A (ko) 2005-05-06
ES2240829T3 (es) 2005-10-16
JP2005513004A (ja) 2005-05-12
EP1448547B1 (en) 2005-04-20
PL369544A1 (en) 2005-05-02
AU2002351816B2 (en) 2008-03-06
JP4188837B2 (ja) 2008-12-03
CN1585762A (zh) 2005-02-23
ATE293619T1 (de) 2005-05-15
CN100516061C (zh) 2009-07-22

Similar Documents

Publication Publication Date Title
MXPA04004308A (es) Derivados de piridina como ligandos del receptor n-metil-d-aspartato (nmda).
SE0104332D0 (sv) Therapeutic agents
HUP0102471A2 (hu) 4-Benzil-piperidin alkilszulfoxid heterociklusok és használatuk altípus-szelektív NMDA antagonistaként és ezeket tartalmazó gyógyszerkészítmények
WO2002022602A3 (en) Triazole compounds useful as protein kinase inhibitors
MY136270A (en) Processes and intermediates for preparing anti-cancer compounds
EP1423370A4 (en) COMPOUNDS BINDING TO THE NUCLEAR FXR-NR1H4 RECEPTOR
ATE266013T1 (de) 1-phenyl-4-benzylpiperazine: spezifische liganden für den dopamin rezeptor (d4)
AU6272301A (en) 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
MXPA04000532A (es) Derivados de 8-metoxi-(1,2,4)-triazolo(1,5-a)piridina y su uso como ligandos receptores de adenosina.
DE69120100T2 (de) Annelierte Thiophen-Derivate, ihre Herstellung und Verwendung
TW200621753A (en) Pyrimidinylimidazoles and methods of making and using the same
MXPA04005847A (es) Compuestos derivados de 4-sulfuro/sulfoxido/sulfonil-1h-pirazolilo, para uso en enfermedades asociadas con el receptor 5-ht2c.
HK1155146A1 (zh) 作為藥物活性劑的茚衍生物
JO2321B1 (en) 4-phenyl-pyridine derivatives
MY138826A (en) 2,7-substituted indoles
AP2001002191A0 (en) 3,3- Biarylpiperine and 2,2-biarylmorpholine derivatives.
PL339143A1 (en) Tetrahydro-gamma-carbolynes
BG104983A (en) Aryl fused azapolycyclic compounds
NZ334736A (en) Acylaminoalkenylene-amide derivatives useful in treatments of the respiratory diseases where it is more specific for NK1 than NK2
ZA982137B (en) Cycloalkylalkanecarboxamides and their preparation and use.
CA2375671A1 (en) 4-phenyl-pyrimidine derivatives
MXPA04003935A (es) Derivados de piridina como bloqueadores del subtipo de receptores n-metil-d-aspartato.
MXPA04005077A (es) Derivados de benzotiazol.
PL1636217T3 (pl) 1-Imidazobenzotiazole jako ligandy receptora adenozynowego
MY139382A (en) New derivatives of artemisinin , and their uses in the treatment of malaria

Legal Events

Date Code Title Description
FG Grant or registration